Clinical trial 2026-525303-27-00 · Non-small cell lung cancer (NSCLC)
2026-525303-27-00 — is «authorised» on CTIS (EU Clinical Trials Information System).
Clinical trial 2026-525303-27-00 (phase II) is «authorised» on CTIS (EU Clinical Trials Information System).
Condition: Non-small cell lung cancer (NSCLC) · Registered interventions: ivonescimab, Paclitaxel Teva 6 mg/ml concentrado para solución para perfusión EFG, Carboplatino Teva 10 mg/ml Concentrado para solución para perfusión · Recorded dates (source): 2026-11-12.
Source: https://euclinicaltrials.eu/ctis-public/view/2026-525303-27-00